144465-94-1

Basic information

• Product Name: 1-(2-Pyridinyl)-4-piperidinamine
• Synonyms: 1-(2-Pyridinyl)-4-piperidinamine
• CAS NO: 144465-94-1
• Molecular Formula: C₁₀H₁₅N₃
• Molecular Weight: 177.25
• Product Categories: pharmacetical
• Mol File: 144465-94-1.mol

Chemical Properties

• Boiling Point: 318.7°Cat760mmHg
• Flash Point: 146.6°C
• Appearance: /
• Density: 1.09g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.562
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 9.90±0.20(Predicted)
• CAS DataBase Reference: 1-(2-Pyridinyl)-4-piperidinamine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-Pyridinyl)-4-piperidinamine(144465-94-1)
• EPA Substance Registry System: 1-(2-Pyridinyl)-4-piperidinamine(144465-94-1)

Safety Data

• Hazardous Substances Data: 144465-94-1(Hazardous Substances Data)

Usage

Uses

1. Used in Pharmaceutical Industry:
1-(2-Pyridinyl)-4-piperidinamine is used as a key intermediate in the synthesis of various pharmaceutical compounds, particularly those targeting the central nervous system. Its unique chemical structure allows for the development of novel drugs with potential therapeutic applications.
2. Used in the Preparation of Peripherally Selective Cannabinoid-1 (CB1) Receptor Agonists:
1-(2-Pyridinyl)-4-piperidinamine is utilized as a building block in the creation of peripherally selective CB1 receptor agonists. These agonists have potential applications in the treatment of various medical conditions, such as obesity, metabolic disorders, and pain management, without causing the psychoactive effects associated with non-selective CB1 agonists.

InChI:InChI=1/C10H15N3/c11-9-4-7-13(8-5-9)10-3-1-2-6-12-10/h1-3,6,9H,4-5,7-8,11H2

Upstream product

• 441330-00-3 (3,4,5,6-Tetrahydro-2H-[1,4']bipyridinyl-4-yl)-carbamic acid tert-butyl ester 
• 1427504-20-8 2-(4-azidopiperidin-1-yl)pyridine 
• 180695-80-1 tert-butyl 4-azidopiperidine-1-carboxylate 
• 109-04-6 2-bromo-pyridine 
• 73874-95-0 (piperidin-4-yl)carbamic acid tert-butyl ester 
• 252578-12-4 (3,4,5,6-tetrahydro-2H-(1,2')bipyridinyl-4-yl)-carbamic acid tert-butyl ester 

Downstream Products

• 1201691-91-9 4-(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-3-methoxy-N-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-benzamide 
• 288-32-4 1H-imidazole 
• 380222-42-4 N-(1-(pyridin-2-yl)piperidin-4-yl)-1H-imidazole-1-carboxamide 

Relevant articles and documents

Disubstituted 1-aryl-4-aminopiperidine library synthesis using computational drug design and high-throughput batch and flow technologies

A platform that incorporates computational library design, parallel solution-phase synthesis, continuous flow hydrogenation, and automated high throughput purification and reformatting technologies was applied to the production of a 120-member library of 1-aryl-4-aminopiperidine analogues for drug discovery screening. The application described herein demonstrates the advantages of computational library design coupled with a flexible, modular approach to library synthesis. The enabling technologies described can be readily adopted by the traditional medicinal chemist without extensive training and lengthy process development times.

4- (4-CYANOPHENYL) -1- (3-TRIFLUOROMETHYLPHENYL) -3,4, 6, 7-TETRAHYDRO-1H-PYRROLO [3, 4- D] PYRIMIDINE-2, 5-DIONE DERIVATIVES AND THEIR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS

Thirty six specific compounds having human neutrophil elastase inhibitory activity are disclosed, one of which has the structural formula (1). The compounds are useful inter alia for the treatment of inflammatory respiratory disease, and may be administer

Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)

The present invention relates to compounds that inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclero

Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)

The present invention relates to compounds which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atheroscler

PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV)

The present invention relates to compounds which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases.

Inhibitors of factor Xa

Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.

NEW COMPOUNDS

The present invention relates to new, potent DPP-IV enzyme inhibitors of the general formula (I), which contain fluorine atoms.

Phenoxylpropanolamines, method for the production thereof and pharmaceutical compositions containing the same

The invention concerns compounds of formula (Ia) wherein R1arepresents hydrogen, an —S(O)z—(C1-C4)Alk group, a —CO(C1-C4)Alk group, an —NHSO2—(C1-C4)Alk group, an NCHl (C1-C4) Alk group, a 2-furyl group or a halogen; R2represents hydrogen or a (C1-C4)Alk group, a (C1-C4) alkoxyl group, a halogen, —COOH, —COO(C1-C4)Alk, —CN, —CONR3R4, —NO2, —SO2NH2, —NHSO2(C1-C4)Alk; m and n are independently 0, 1 or 2; R3and R4independently represent hydrogen or a (C1-C4)Alk group; Z is 1 or 2 and their salts or solvates, the pharmaceutical compositions that contain them, the process for their preparation, and intermediate synthesis products.

Inhibitors of factor Xa

Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.